MA38208B1 - Inhibiteurs de bmi-1 pyrimidines inversés substitués - Google Patents

Inhibiteurs de bmi-1 pyrimidines inversés substitués

Info

Publication number
MA38208B1
MA38208B1 MA38208A MA38208A MA38208B1 MA 38208 B1 MA38208 B1 MA 38208B1 MA 38208 A MA38208 A MA 38208A MA 38208 A MA38208 A MA 38208A MA 38208 B1 MA38208 B1 MA 38208B1
Authority
MA
Morocco
Prior art keywords
bmi
inhibitors
substituted
inhibit
function
Prior art date
Application number
MA38208A
Other languages
English (en)
Inventor
Chang-Sun Lee
Ramil Baiazitov
Liangxian Cao
Thomas Davis
Wu Du
Ronggang Liu
Young-Choon Moon
Steven Paget
Hongyu Ren
Nadiya Sydorenko
Richard Wilde
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MA38208B1 publication Critical patent/MA38208B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

L'invention concerne des composés pyrimidines inversés substitués aminés et des formes de ceux-ci qui inhibent la fonction et réduisent le taux d'une protéine de site 1 d'intégration du virus de la leucémie murine de moloney spécifique des lymphocytes b (bmi-1) et leurs procédés d'utilisation pour inhiber la fonction de bmi-1 et réduire le taux de bmi-1 pour traiter un cancer à médiation par bmi-1.
MA38208A 2012-11-21 2013-11-21 Inhibiteurs de bmi-1 pyrimidines inversés substitués MA38208B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
PCT/US2013/071132 WO2014081906A2 (fr) 2012-11-21 2013-11-21 Inhibiteurs de bmi-1 pyrimidines inversés substitués

Publications (1)

Publication Number Publication Date
MA38208B1 true MA38208B1 (fr) 2021-12-31

Family

ID=50776672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38208A MA38208B1 (fr) 2012-11-21 2013-11-21 Inhibiteurs de bmi-1 pyrimidines inversés substitués

Country Status (32)

Country Link
US (3) US10428050B2 (fr)
EP (1) EP2922828B1 (fr)
JP (3) JP6412503B2 (fr)
KR (4) KR20220143164A (fr)
CN (2) CN104918919A (fr)
AR (1) AR093579A1 (fr)
AU (1) AU2013348009C1 (fr)
BR (1) BR112015011760B1 (fr)
CA (1) CA2892045C (fr)
CL (1) CL2015001377A1 (fr)
CR (1) CR20150294A (fr)
CU (1) CU24387B1 (fr)
DK (1) DK2922828T3 (fr)
EA (2) EA035349B1 (fr)
EC (1) ECSP15019948A (fr)
ES (1) ES2821529T3 (fr)
HK (1) HK1215032A1 (fr)
IL (2) IL238871B (fr)
MA (1) MA38208B1 (fr)
MX (2) MX385385B (fr)
NI (1) NI201500072A (fr)
NZ (2) NZ746607A (fr)
PE (1) PE20151413A1 (fr)
PH (1) PH12015501130B1 (fr)
PL (1) PL2922828T3 (fr)
PT (1) PT2922828T (fr)
SA (1) SA517381847B1 (fr)
SG (2) SG11201503982XA (fr)
TW (1) TWI623531B (fr)
UA (1) UA118094C2 (fr)
WO (1) WO2014081906A2 (fr)
ZA (1) ZA201503642B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220143164A (ko) 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN105593215B (zh) * 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
AR093580A1 (es) * 2013-08-30 2015-06-10 Ptc Therapeutics Inc Inhibidores bmi-1 de pirimidina sustituidos
WO2015076800A1 (fr) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Inhibiteurs de bmi-1 à base de pyridine et de pyrazine substituées
US10874355B2 (en) 2014-04-24 2020-12-29 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
CN108602775B (zh) * 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
CN118609834A (zh) 2016-11-14 2024-09-06 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
CA3053245A1 (fr) 2017-02-09 2018-08-16 Cognoa, Inc. Plate-forme et systeme de medecine personnalisee numerique
WO2019028171A1 (fr) 2017-08-01 2019-02-07 Ptc Therapeutics, Inc. Inhibiteur de dhodh pour utilisation dans le traitement de cancers hématologiques
EP3564235A1 (fr) * 2018-05-03 2019-11-06 Northwestern University Dérivés n-hétérocycliques aromatiques en tant qu'inhibiteurs de kinase de protéine kinase activée par mitogène interagissant sur la kinase 1 (mnk1) et 2 (mnk2)
CN113164479A (zh) * 2018-08-17 2021-07-23 Ptc医疗公司 用于治疗胰腺癌的方法
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
WO2020150326A1 (fr) * 2019-01-15 2020-07-23 Ptc Therapeutics, Inc. Méthode de traitement d'une leucémie aiguë myéloïde
EA202192117A1 (ru) * 2019-02-28 2021-11-23 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ лечения множественной миеломы
SG11202109503TA (en) * 2019-03-11 2021-09-29 Ptc Therapeutics Inc Compound form having enhanced bioavailability and formulations thereof
CA3134521A1 (fr) 2019-03-22 2020-10-01 Cognoa, Inc. Procedes et dispositifs de therapie numerique personnalisee
MX2021011688A (es) * 2019-03-27 2022-01-24 Ptc Therapeutics Inc Combinaciones utiles en un metodo para tratar sarcoma.
US20220177459A1 (en) * 2019-04-02 2022-06-09 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
US12564342B2 (en) 2019-09-06 2026-03-03 Cognoa, Inc. Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (fr) * 1973-09-20 1977-11-30 Delalande Sa
JP2896532B2 (ja) 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
IN188411B (fr) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
WO2001025220A1 (fr) 1999-10-07 2001-04-12 Amgen Inc. Inhibiteurs de triazine kinase
ATE311385T1 (de) 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
EP1257546A1 (fr) 2000-02-17 2002-11-20 Amgen Inc. Inhibiteurs de kinases
EP1274705A1 (fr) 2000-03-29 2003-01-15 Cyclacel Limited 4-heteroaryle-pyrimidines substituees en 2 et leur utilisation dans le traitement de troubles proliferants
EP1317450B1 (fr) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
CA2423050A1 (fr) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP1423388B1 (fr) 2001-02-20 2008-12-03 AstraZeneca AB 2-arylamino-pyrimidines pour le traitement de troubles associes a gsk3
DE60239097D1 (de) 2001-03-02 2011-03-17 Gpc Biotech Ag Drei-hybrid-assaysystem
CA2450555A1 (fr) 2001-06-25 2003-01-03 Merck & Co., Inc. Composes d'heteroaryle fondus (pyrimidyle)(phenyle) substitues inhibiteurs de p38 et de la kinase pkg
WO2003004492A1 (fr) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines utilisees en tant qu'inhibiteurs des proteines kinases src et lck
WO2003011837A1 (fr) 2001-08-01 2003-02-13 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
WO2003075828A2 (fr) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Composes utiles pour le traitement du cancer
NZ537156A (en) 2002-05-23 2007-06-29 Cytopia Pty Ltd Kinase inhibitors
WO2004002963A1 (fr) 2002-06-28 2004-01-08 Nippon Shinyaku Co., Ltd. Derive d'amide
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (fr) 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Nouveau reactifs de marquage au fluor et de piegeage et procedes de synthese et d'utilisation correspondants
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1551842A1 (fr) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Composes de pyradazine utiles comme inhibiteurs de gsk-3
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
TWI372624B (en) * 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006093247A1 (fr) 2005-02-28 2006-09-08 Japan Tobacco Inc. NOUVEAU COMPOSÉ AMINOPYRIDINE AYANT UNE ACTIVITÉ D'INHIBITION DE LA Syk
KR20080004488A (ko) 2005-03-10 2008-01-09 바이엘 파마슈티칼스 코포레이션 과다증식성 장애 치료용 피리미딘 유도체
CA2654358A1 (fr) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Derives de pyridine et de pyrazine utilises en tant qu'inhibiteurs de la kinase mnk
CA2665398A1 (fr) 2006-10-03 2008-04-10 Neurosearch A/S Derives d'indazolyle utiles en tant qu'agents modulant les canaux potassiques
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
US7968556B2 (en) * 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
CA2672518A1 (fr) 2006-12-22 2008-07-03 Novartis Ag Composes organiques et leurs utilisations
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
CA2676715A1 (fr) 2007-02-12 2008-08-21 Merck & Co., Inc. Derives de piperazine pour le traitement de la maladie d'alzheimer et des conditions apparentees
WO2008132502A1 (fr) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrimidines substitués par pyrazolyle-amino et leur utilisation dans le traitement du cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
WO2009037247A1 (fr) 2007-09-17 2009-03-26 Neurosearch A/S Dérivés de pyrazine et leur utilisation en tant que modulateurs des canaux potassiques
WO2009064835A1 (fr) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines et 4-pyrazolyl-n-hétéroarylpyrimidin-2-amines en tant qu'inhibiteurs de janus kinase
CA2707989A1 (fr) 2007-12-07 2009-06-11 Novartis Ag Derives de pyrazole et leur utilisation comme inhibiteurs de kinases dependantes des cyclines
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
ES2605815T3 (es) 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
CN102177154A (zh) 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
WO2010061903A1 (fr) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Dérivé de pyrimidine et dérivé de pyridine présentant tous deux une activité inhibitrice de pi3k
US20120165309A1 (en) 2009-02-12 2012-06-28 Astellas Pharma Inc. Hetero ring derivative
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2767091A1 (fr) 2009-07-15 2011-01-20 Abbott Laboratories Inhibiteurs des pyrrolopyrazines kinases
CA2767089A1 (fr) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridines inhibiteurs de kinases
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
MX2012008083A (es) 2010-01-12 2012-08-15 Ab Science Inhibidores de triazol y oxazol quinaza.
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
BR112013003031A2 (pt) * 2010-08-19 2016-06-14 Hoffmann La Roche método de produção de células hastes neurais (chn), células hastes neurais e seu uso, composição terapêutica e banco biológico de nscs
CN103221408A (zh) 2010-09-13 2013-07-24 诺瓦提斯公司 三嗪-*二唑类化合物
WO2012050884A2 (fr) 2010-09-28 2012-04-19 President And Fellows Of Harvard College Glycosides cardiaques qui sont de puissants inhibiteurs de l'expression du gène de l'interféron bêta
CA2819373A1 (fr) 2010-12-09 2012-06-14 Amgen Inc. Composes bicycliques en tant qu'inhibiteurs de pim
PL2678332T3 (pl) 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
JP6116554B2 (ja) 2011-07-07 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんの処置のための置換されたアザ複素環
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR20220143164A (ko) * 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
SG11202109503TA (en) * 2019-03-11 2021-09-29 Ptc Therapeutics Inc Compound form having enhanced bioavailability and formulations thereof

Also Published As

Publication number Publication date
AU2013348009C1 (en) 2019-08-08
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (fr) 2014-05-30
JP6918898B2 (ja) 2021-08-11
KR20150086345A (ko) 2015-07-27
JP2020055815A (ja) 2020-04-09
NZ746607A (en) 2019-11-29
TW201427972A (zh) 2014-07-16
ES2821529T3 (es) 2021-04-26
AU2013348009B2 (en) 2018-05-17
NZ708909A (en) 2019-11-29
CU20150053A7 (es) 2015-11-27
EP2922828A2 (fr) 2015-09-30
US20220064150A1 (en) 2022-03-03
MX2021009892A (es) 2021-09-14
CN104918919A (zh) 2015-09-16
CR20150294A (es) 2015-08-20
PE20151413A1 (es) 2015-10-23
BR112015011760A2 (pt) 2017-07-11
BR112015011760B1 (pt) 2022-12-06
KR20220016305A (ko) 2022-02-08
NI201500072A (es) 2016-01-18
PT2922828T (pt) 2020-10-12
EA201590992A1 (ru) 2015-11-30
IL265253A (en) 2019-05-30
SG10201600149VA (en) 2016-02-26
US10428050B2 (en) 2019-10-01
CN111423417A (zh) 2020-07-17
US11180483B2 (en) 2021-11-23
ZA201503642B (en) 2020-10-28
JP2019031509A (ja) 2019-02-28
UA118094C2 (uk) 2018-11-26
ECSP15019948A (es) 2016-01-29
KR20220143164A (ko) 2022-10-24
EA201890142A1 (ru) 2018-06-29
MX2015006469A (es) 2015-10-29
PH12015501130A1 (en) 2015-08-03
TWI623531B (zh) 2018-05-11
AR093579A1 (es) 2015-06-10
EP2922828A4 (fr) 2016-07-27
US20200024260A1 (en) 2020-01-23
US20150315182A1 (en) 2015-11-05
HK1215032A1 (zh) 2016-08-12
CN111423417B (zh) 2022-11-15
PL2922828T3 (pl) 2020-12-28
CU24387B1 (es) 2019-03-04
CL2015001377A1 (es) 2016-02-19
SG11201503982XA (en) 2015-06-29
JP2016504290A (ja) 2016-02-12
EP2922828B1 (fr) 2020-07-08
KR102275676B1 (ko) 2021-07-12
IL238871B (en) 2019-03-31
JP6617186B2 (ja) 2019-12-11
EA031405B1 (ru) 2018-12-28
KR20210088740A (ko) 2021-07-14
DK2922828T3 (da) 2020-08-31
WO2014081906A3 (fr) 2014-07-17
AU2013348009A1 (en) 2015-06-04
MX385385B (es) 2025-03-18
EA035349B1 (ru) 2020-05-29
CA2892045A1 (fr) 2014-05-30
KR102455889B1 (ko) 2022-10-17
CA2892045C (fr) 2022-05-31
PH12015501130B1 (en) 2023-01-27
IL238871A0 (en) 2015-07-30
JP6412503B2 (ja) 2018-10-24
KR102356487B1 (ko) 2022-02-08

Similar Documents

Publication Publication Date Title
MA38208B1 (fr) Inhibiteurs de bmi-1 pyrimidines inversés substitués
MA48772B1 (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
EA201690502A1 (ru) Замещенные пиримидиновые ингибиторы bmi-1
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
MX2021007538A (es) Derivados biciclicos.
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MA39285A (fr) Peptides macrocycliques utiles comme immunomoldulateurs
EP3661691A4 (fr) Système de traitement laser d'une surface de tuyau
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MX2021007540A (es) Derivados biciclicos.
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA67726B1 (fr) Utilisations thérapeutiques de dérivés deutérés du lanifibranor
EA201792182A1 (ru) Композиции и способы для лечения анемии
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
EP3769829A4 (fr) Ensemble d'éléments de bloc
MA41203B1 (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
FR3082427B1 (fr) Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
MA49607B2 (fr) ANTICORPS MONOCLONAL POUR IL-5Rα
EP3966204A4 (fr) 1-amino-1h-imidazole-5-carboxamide substitué utilisé en tant qu'inhibiteurs de la tyrosine kinase de bruton
EP3802583A4 (fr) Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie
EP3787646A4 (fr) Administration intradiscale de cellules t régulatrices pour le traitement d'une discopathie dégénérative